195 related articles for article (PubMed ID: 38343541)
1. Editorial: Immunotherapy and multimodality therapy for lung cancer.
Song C; Liu W; Wan Y; Mao W
Front Immunol; 2024; 15():1372513. PubMed ID: 38343541
[No Abstract] [Full Text] [Related]
2. Multimodality Therapy for NSCLC.
Du L; Waqar SN; Morgensztern D
Cancer Treat Res; 2016; 170():151-63. PubMed ID: 27535393
[TBL] [Abstract][Full Text] [Related]
3. [Recent Advances in Immunotherapy for Non-Small Cell Lung Cancer].
Muto S; Suzuki H
Gan To Kagaku Ryoho; 2018 Feb; 45(2):212-216. PubMed ID: 29483407
[TBL] [Abstract][Full Text] [Related]
4. The Combined Use of SBRT and Immunotherapy-a Literature Review.
Lubas MJ; Kumar SS
Curr Oncol Rep; 2020 Sep; 22(12):117. PubMed ID: 32929678
[TBL] [Abstract][Full Text] [Related]
5. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer.
Fitzgerald K; Simone CB
Thorac Surg Clin; 2020 May; 30(2):221-239. PubMed ID: 32327181
[TBL] [Abstract][Full Text] [Related]
6. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
Santana-Davila R; Chow LQ
Future Oncol; 2018 Feb; 14(3):191-194. PubMed ID: 29334785
[No Abstract] [Full Text] [Related]
7. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
[TBL] [Abstract][Full Text] [Related]
8. Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibition in Combination With Chemotherapy: A Brief Report.
Shantzer LB; Dougherty SC; Bolte F; Melson JW; Reed DR; Lynch AC; Gentzler RD; Novicoff W; Hall RD
Clin Lung Cancer; 2023 Mar; 24(2):e60-e64. PubMed ID: 36526550
[No Abstract] [Full Text] [Related]
9. Multimodality therapy for lung cancer.
Perry MC
Mo Med; 1989 Nov; 86(11):733-4. PubMed ID: 2554107
[No Abstract] [Full Text] [Related]
10. Immunotherapy for non-small cell lung cancer: are we on the cusp of a new era?
Waqar SN; Morgensztern D
Expert Rev Clin Immunol; 2015; 11(8):871-3. PubMed ID: 26051156
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy for non-small cell lung cancer.
Evans WK
Chest; 1989 Jul; 96(1 Suppl):87S-91S. PubMed ID: 2544378
[No Abstract] [Full Text] [Related]
12. Complete Response to Immunotherapy Plus Chemotherapy After an Unusual Clinical Response to Afatinib and Stereotactic Radiosurgery in a Patient With Metastatic EGFR-Mutant Non-Small-Cell Lung Cancer.
Pizarro G; Pinto MP; Muñoz-Medel M; Cordova-Delgado M; Bravo ML; Nervi B; Sánchez C; Ibañez C; Peña J; Walbaum B; Madrid J; Briones J; Koch E; Valbuena J; Gonzalez S; Gejman R; Acevedo F; Mondaca S; Garrido M; Vines E; Galindo H
Clin Lung Cancer; 2020 Jul; 21(4):e250-e254. PubMed ID: 32088114
[No Abstract] [Full Text] [Related]
13. Investigation chemotherapy in multimodality therapy of non-small cell lung cancer.
Vokes EE
Front Radiat Ther Oncol; 1992; 26():64-71. PubMed ID: 1324877
[No Abstract] [Full Text] [Related]
14. Cytokine immunotherapy of non-small cell lung cancer.
Dubinett SM; Kradin RL
Reg Immunol; 1993; 5(3-4):232-43. PubMed ID: 8240940
[No Abstract] [Full Text] [Related]
15. Multimodality treatment in locally advanced non-small cell lung cancer.
Trodella L; D'Angelillo RM; Ramella S; Granone P
Ann Oncol; 2006 Mar; 17 Suppl 2():ii32-33. PubMed ID: 16608977
[No Abstract] [Full Text] [Related]
16. Dendritic Cell-Based Immunotherapy in Lung Cancer.
Stevens D; Ingels J; Van Lint S; Vandekerckhove B; Vermaelen K
Front Immunol; 2020; 11():620374. PubMed ID: 33679709
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
18. [Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)].
Simonneau Y; Ruppert AM; Chaabane N; Lavolé A; Wislez M
Bull Cancer; 2018 Oct; 105(10):854-856. PubMed ID: 30262415
[No Abstract] [Full Text] [Related]
19. Emerging Therapies in Thoracic Malignancies-Immunotherapy, Targeted Therapy, and T-Cell Therapy in Non-Small Cell Lung Cancer.
Sepesi B; Cascone T; Chun SG; Altan M; Le X
Surg Oncol Clin N Am; 2020 Oct; 29(4):555-569. PubMed ID: 32883458
[TBL] [Abstract][Full Text] [Related]
20. Current Management of Stage IIIA (N2) Non-Small-Cell Lung Cancer: Role of Perioperative Immunotherapy, and Tyrosine Kinase Inhibitors.
Bryan DS; Donington JS
Thorac Surg Clin; 2023 May; 33(2):189-196. PubMed ID: 37045488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
